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Abstract
Background: Methyl-CpG-binding protein 2 (MeCP2), a protein with affinity for methylated cytosines, is crucial for
neuronal development and function. MeCP2 regulates gene expression through activation, repression and chromatin
remodeling. Mutations in MeCP2 cause Rett syndrome, and these patients display impaired nociception. We observed
an increase in MeCP2 expression in mouse dorsal root ganglia (DRG) after peripheral nerve injury. The functional
implication of increased MeCP2 is largely unknown. To identify regions of the genome bound by MeCP2 in the DRG
and the changes induced by nerve injury, a chromatin immunoprecipitation of MeCP2 followed by sequencing (ChIPseq) was performed 4 weeks after spared nerve injury (SNI).
Results: While the number of binding sites across the genome remained similar in the SNI model and sham control,
SNI induced the redistribution of MeCP2 to transcriptionally relevant regions. To determine how differential binding
of MeCP2 can affect gene expression in the DRG, we investigated mmu-miR-126, a microRNA locus that had enriched
MeCP2 binding in the SNI model. Enriched MeCP2 binding to miR-126 locus after nerve injury repressed miR-126
expression, and this was not mediated by alterations in methylation pattern at the miR-126 locus. Downregulation
of miR-126 resulted in the upregulation of its two target genes Dnmt1 and Vegfa in Neuro 2A cells and in SNI model
compared to control. These target genes were significantly downregulated in Mecp2-null mice compared to wildtype littermates, indicating a regulatory role for MeCP2 in activating Dnmt1 and Vegfa expression. Intrathecal delivery
of miR-126 was not sufficient to reverse nerve injury-induced mechanical and thermal hypersensitivity, but decreased
Dnmt1 and Vegfa expression in the DRG.
Conclusions: Our study shows a regulatory role for MeCP2 in that changes in global redistribution can result in direct
and indirect modulation of gene expression in the DRG. Alterations in genome-wide binding of MeCP2 therefore
provide a molecular basis for a better understanding of epigenetic regulation-induced molecular changes underlying
nerve injury.
Keywords: MeCP2, Dorsal root ganglia, Pain, MicroRNA, ChIP-seq, Epigenetics
Background
Epigenetic modifications resulting from DNA methylation play a critical role in cellular differentiation, development [1] and may contribute to disease including
peripheral and central pain sensation and processing [2].
DNA methylation is mediated by DNA methyltransferase
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(DNMT) catalyzing the transfer of a methyl group onto
the 5′ position of cytosine. MeCP2 can decipher methylation patterns across the genome before binding to
methylated DNA [1] and can mediate downstream
transcriptional changes of a large number of genes [3].
Depending on its interacting protein partners and target
genes, MeCP2 can act as either an activator or repressor
[4]. MeCP2 can also play a role in dampening genomewide transcriptional noise in a DNA methylationdependent manner [5]. Mutations in MECP2 result in
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the neurodevelopmental disorder Rett syndrome (RTT)
[6]. Among the many symptoms associated with RTT,
alterations in pain sensitivity are reported to be as high
as 75 % [7]. Reduced sensitivity has been observed in
mouse models with RTT and autism-associated mutations [8–11]. The observations from RTT patients and
MeCP2-mutant mice indicate that MeCP2 contributes
either directly or indirectly to reduced pain sensitivity.
Our previous study has shown that MeCP2 expression
was altered in mouse dorsal root ganglia (DRG) following
spared nerve injury (SNI). While we observed upregulation of MeCP2 protein 4 weeks post-surgery [10], others have reported downregulation at earlier time points
and in subsets of damaged neurons in the DRG [11, 12].
MeCP2 has previously been linked to inflammatory pain.
Inflammatory stimulus was shown to increase phosphorylation of MeCP2 in lamina I neurons in the dorsal horn,
resulting in its dissociation from the genome, thereby
alleviating repression of genes linked to pain [13]. MeCP2
has also been associated with central mechanisms of pain
through regulation of a transcriptional repressor, histone
dimethyltransferase G9a, resulting in increased expression of brain-derived neurotrophic factor [14].
MeCP2 is highly expressed in neurons and glia [5]. The
dynamic expression of MeCP2 in the DRG after nerve
injury [10] suggests a role for MeCP2 in pain modulation
through transcriptional regulation. DRG are major players
responsible for conveying noxious stimuli from the periphery to the central nervous system. MeCP2 is predominantly
a nuclear protein and cell bodies of nociceptive sensory
neurons are located in DRG, with two axonal branches projecting to the periphery and to the dorsal horn of the spinal
cord. Genome-wide studies investigating MeCP2 binding
patterns have been conducted in neurons, astrocytes and
different regions of the brain [5, 15–17]. To investigate the
role of MeCP2 in mediating nociception, and to determine
changes in MeCP2 binding patterns after nerve injury,
we performed chromatin immunoprecipitation followed
by massively parallel sequencing (ChIP-seq) in mouse
DRG 4 weeks after SNI surgery. We observed a genomewide redistribution of MeCP2 binding and evaluated how
changes in binding patterns directly and indirectly regulate
genes that contribute to the pathology of pain.

Methods
Animal model of neuropathic pain

The care and use of all mice were approved by the Institutional Animal Care & Use Committee of Drexel University College of Medicine. The SNI model was generated
using 8-week-old C57BL/6 male mice (Taconic) as previously described [18, 19]. Briefly, mice were anesthetized
with isoflurane during surgery. The common peroneal
and tibial nerves of the left paw were ligated, and 2–4 mm
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of the nerve was sectioned and removed distal to ligation.
Sham mice underwent the same surgical procedures as
the SNI group without ligation and sectioning. Development of mechanical hypersensitivity was assessed using
von Frey filaments [18]. L4, L5 and L6 DRG on the ipsilateral side of surgery were collected 4 weeks post-SNI
surgery at 12 weeks of age.
Mecp2‑null mice

DRG from approximately 12-week-old male hemizygous
Mecp2-null (Mecp2−/y) mice and wild-type littermates
(Mecp2+/y) were collected for molecular characterization [20]. These mice do not have detectable Mecp2 gene
product and were used to study gene expression in the
absence of MeCP2.
Chromatin immunoprecipitation (ChIP) of MeCP2

ChIP was performed using protocols adapted from Covaris truChIP chromatin shearing kit tissue SDS and Millipore magna ChIP G tissue kits. Ipsilateral L4, L5 and L6
DRG were collected 4 weeks after SNI or sham surgery.
DRG were pooled from ten mice per sample, in duplicate. Samples were washed 3 times in phosphate-buffered
saline (PBS) containing protease inhibitors (PI). Chromatin was crosslinked to DNA using 1 % methanol-free
formaldehyde and incubated at room temperature for
5 min with rotation. Samples were then incubated with
Covaris quenching buffer for 5 min at room temperature
with rotation to quench the formaldehyde crosslinking.
Samples were washed 3 times for 5 min with PBS containing PI. Tissue samples were resuspended in Covaris
lysis buffer containing PI, incubated on ice for 10 min
and homogenized by pipetting. After 10-min incubation
on ice, nuclei were pelleted at 1700×g for 5 min at 4 °C.
Samples were washed using 1 ml Covaris wash buffer,
pellets resuspended in 130 µl Covaris SDS shearing buffer
containing PI and incubated on ice for 10 min. Chromatin was sheared using the Covaris M220. Insoluble
material was pelleted by centrifugation at 10,000×g for
5 min. Five microliters of the supernatant was removed
for input samples. To each sample, 20 µl of Protein G
magnetic beads and 5 µl rabbit anti-MeCP2 antibody
[21, 22] or 5 µl rabbit serum was added and incubated
overnight at 4 °C with rotation. Beads were pelleted with
a magnetic separator, washed and resuspended in Millipore elution buffer containing proteinase K, followed
by incubations at 62 °C overnight, and 95 °C for 10 min.
Supernatant was used for DNA purification according to
manufacturer’s instructions. For identification of MeCP2
binding to miR-126, PCR was performed using DNA isolated from DRG. Primer sequences used were: Forward:
TATTTTGAAGAGGTTTTTGGAAGG and Reverse:
CCAAAACACACAACTAACTAAAAACAA.

Manners et al. Epigenetics & Chromatin (2016) 9:23

Sequence alignment and filtering

Single-end 50-base reads were generated on the Applied
Biosystems (AB) SOLiD 5500xl platform. Reads were
mapped to the mm10 genome using AB LifeScope 2.5.1
software. Reads in each sample were filtered out based on
their mapping quality, to eliminate poorly mapping reads
and reads that may map to multiple places in the genome,
and only reads MAPQ ≥ 10 were used for peak calling
and tag enrichment analysis. Samtools [23] merge was
used to pool replicates for each IP condition, and samtools rmdup was used to remove duplicate reads so that
only unique tags were used for peak calling.
Peak calling

The HOMER (Hypergeometric Optimization of Motif
EnRichment) suite [24] was used for peak calling on the
sham and SNI IP sequence libraries, using respective
sham and SNI input libraries as control. HOMER ChIPseq tag directories were created from the set of unique
mapped reads for each IP and input condition. HOMER
peak calling (findPeaks) was performed for both narrow
peaks (-style factor) and broad peaks (-style histone).
Visual review of the sequence tags in the Integrated
Genomics Viewer (IGV) [25] was used to decide whether
narrow or broad peaks were a better fit for MeCP2 binding patterns. The set of broad peaks was selected as the
better representation of MeCP2 binding and used for
subsequent annotation and interpretation. HOMER was
also used to identify differential binding between sham
and SNI, using the getDifferentialPeaks tool, with default
settings to identify peaks with fourfold more tags in one
condition versus the other, with p value less than 0.0001.
Annotation

The HOMER annotation database v5.4 for mouse was
used in conjunction with the HOMER annotation tool
(annotatePeaks) to identify the closest genomic feature
to each peak, as well as enrichment statistics for genomic
regions including promoters, exons, introns, intergenic
regions. Annotation was performed on the set of all sham
peaks, all SNI peaks, as well as differentially bound peaks
in sham and SNI. The HOMER annotatePeaks tool was
also used in mRNA and miRNA mode to analyze tag
enrichment and peak locations with respect to all annotated genes and miRNAs.
Cell culture and transfection

Neuro 2a cells obtained from American Type Culture
Collection (ATCC) were maintained in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10 %
fetal bovine serum at 37 °C in 5 % CO2. For monitoring
changes in endogenous Dnmt1 and Vegfa expression,
cells were transfected with precursor miR-126 plasmid
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(GeneCopoeia) using X-tremeGENE HP DNA transfection reagent (Roche) for 72 h.
Quantitative RT‑PCR

RNA was purified from the following samples: Neuro
2a cells, DRG collected from SNI model, sham control,
Mecp2-null and wild-type littermate mice using the
mirVana RNA isolation kit (Life technologies). cDNA
synthesis and qRT-PCR for mRNA were performed
as previously described [26]. The Assay ID for TaqMan
primer probes used were Mm00599780_g1 (Dnmt1) and
Mm00437306_m1 (Vegfa). Gapdh was used as a normalizer. cDNA synthesis for miR-126 and detection was conducted using TaqMan microRNA assay (Assay ID 00451,
Applied Biosystems). U6 was used for normalization.
Western blot

Protein from Neuro 2a cells or DRG was isolated using
radioimmunoprecipitation assay buffer (Thermo Scientific).
For Western blotting, 2 µg protein lysate from DRG or 10 µg
from cell pellets was resolved by a 4–12 % SDS-PAGE gel,
transferred to nitrocellulose membrane. The membranes
were probed with 1:500 dilution of Dnmt1 (D63A6) XP
antibody #5032 (Cell Signaling) or 1:1000 Vegfa antibody
(Abcam ab51745) overnight at 4 °C. Chemiluminescence
was detected using FluorChem M System (Protein Simple).
The membrane was also probed with 1:1000 beta tubulin
(9F3) antibody #2128 (Cell Signaling) as a loading control.
Quantification was done using UN-SCAN-IT software, and
Dnmt1 and Vegfa expression was normalized to beta tubulin.
Immunocytochemistry

Neuro 2a cells grown on 12-mm glass coverslips were
transfected with miRNA precursor plasmids with GFP
using X-tremeGENE HP DNA transfection reagent for
72 h. Cells were fixed in 4 % formaldehyde and blocked
with 10 % normal goat serum followed by a 3-h incubation in 1:500 anti-Dnmt1 antibody (mentioned above).
Anti-Rabbit-IgG Atto 647N secondary antibody (Sigma)
was used for detection of Dnmt1. Coverslips were
mounted using Vectashield mounting medium with
DAPI (Vector Laboratories). Images were acquired using
the 60× objective on the Olympus FV1000 confocal
microscope and Fluoview FV10-ASW software. Transfected (GFP positive) and untransfected (GFP negative)
cells were compared.
Intrathecal catheter implantation and miRNA injection

miRNA administration protocol was adapted from previous report of intrathecal miRNA delivery [27]. To administer miRNA mimics, a polyurethane catheter (25G, 5.5 cm
long, SAI infusion) was placed into the intrathecal space of
the lumber L4–L5 vertebrae under isoflurane anesthesia.
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The catheter was stereotactically secured under the skin
and occluded between injections. A custom miRCURY
(Exiqon) miR-126 mimic containing a 5′ cholesterol tag
and 3′ fluorescein label was injected at 2 nmol concentration with 4 µl iFECT transfection reagent (Neuromics).
A total of 6 µl was delivered into the catheter connection
juncture using a 25G blunt end needle on a Hamilton
syringe. The catheter was then flushed with 7 µl sterile PBS
to ensure miRNA reached the intrathecal space.
Bisulfite sequencing and analysis of CpG sites in miR‑126
locus and putative promoter

To analyze the methylation status of CpG dinucleotides
in the miR-126 locus, L4, L5 and L6 DRG were collected
from three SNI or three sham control mice 4 weeks after
surgery. Mouse genomic DNA was isolated using GenElute mammalian genomic DNA minipreps kit (Sigma
Aldrich) and subjected to bisulfite conversion using
the Epitect fast DNA bisulfite kit (Qiagen). The 72-bp
fragment of interest was amplified using the following
primer pairs designed with MethPrimer software [28]:
Forward: TATTTTGAAGAGGTTTTTGGAAGG and
Reverse: CCAAAACACACAACTAACTAAAAACAA.
The 140-bp fragment within the promoter of Egfl7 was
amplified using the following primer pairs: Forward:
GGGAAGGGTTTATTTTAGTTTTGAT and Reverse:
ATCTACTACCCAAAATCCCTCCTAA.
Gene ontology analysis

HOMER peaks for sham and SNI datasets were filtered
to include only peaks within ±2 kb of gene transcription
start sites. Functional analysis was performed on the genes
associated with these peaks by testing for gene ontology
(GO) term enrichment using ToppGene [29]. Functional
analysis was repeated for genes associated with differential
bound peaks around the promoter (±2 kb) using the set
of peaks identified as fourfold higher and sham (fourfold
down in SNI) and the set of peaks identified as fourfold
higher in SNI. Additionally, a tag-based analysis was performed to identify transcribed gene regions with differential tag enrichment, producing a set of genes with fourfold
higher tag enrichment in sham (fourfold down in SNI) and
a set of genes with fourfold higher tag enrichment in SNI
(fourfold up in SNI) with a differential enrichment p value
of 0.01. Functional analysis for enriched GO terms was
then performed on the resulting gene sets.
Statistical methods

For statistical analysis, mean values with standard error
are shown; p values were determined using t tests with
paired or unpaired samples, and significance was set at
p < 0.05.
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Results
MeCP2–DNA binding profiles

To determine nerve injury-induced changes in MeCP2bound chromatin, we conducted ChIP-seq in the DRG
from SNI model and sham control mice. Generation
of the SNI model, confirmation of hypersensitivity and
DRG collection 4 weeks post-surgery have been previously described [10]. ChIP-seq was conducted on DRG
pooled from ten mice per sample. We determined that
MeCP2 binding occurred broadly across the genome,
as previously reported [5, 17]. Enriched binding was
observed in promoter regions and gene bodies for both
protein-coding and noncoding genes in SNI and sham
control DRG (Fig. 1a–c). Table 1 shows the enriched
binding for both coding and noncoding regions in SNI
and sham control DRG and the p values for Fig. 1c. The
number of unique sham IP tags was 2,178,607; unique
sham input tags were 20,020,088, and the total sham
peaks were 85,903. For SNI, the unique SNI IP tags were
2,982,156, unique SNI input tags were 12,917,142, and
total SNI peaks were 88,755. Comparison of MeCP2bound sequences at single base resolution indicates
both distinct and common MeCP2 binding sites to
regions encoding mRNAs in SNI and sham DRG samples (Fig. 1d). GO analysis of our ChIP-seq results (top 10
enriched GO terms with p < 0.01 shown in Table 2, complete list shown in Additional file 1: Table S1) indicates
that MeCP2 binding occurs at the promoter of genes
with neuronal function, ion channel activity and cellular
membrane functions. These results closely correspond
with previous reports of genes repressed by MeCP2 identified in the brain [16].
Genome‑wide redistribution of MeCP2 binding in the DRG
after nerve injury

Comparative analysis of enriched peaks in SNI versus
sham was done to elucidate nerve injury-induced differences in genome-wide MeCP2 binding. A redistribution of MeCP2 binding in SNI as indicated by increased
enrichment within transcribed regions is shown in
Fig. 2a, b. Sham peaks bound fourfold higher than in
SNI (i.e., 4× as many tags) was 56,423; SNI peaks
bound fourfold higher than in sham (i.e., 4× as many
tags) was 17,686. Table 3 shows ten genes with enriched
MeCP2 binding in the promoter and in the gene bodies that have a fourfold increase or decrease (log2 fold
change) between sham and SNI, with p < 0.001. Distinct binding patterns of MeCP2 in SNI could therefore
lead to alterations in the genome, which in turn can
mediate gene expression changes ensuing nerve injury.
Complete ChIP-seq data are shown in Additional file 2:
Table S2.
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Fig. 1 Genome-wide MeCP2-DNA binding profile in the DRG from SNI and sham control mice. a–b Genomic distribution of peaks from ChIP-seq
in the sham and SNI samples. c Enrichment of MeCP2 binding to genomic regions in the SNI and sham models. Enrichment in SNI and sham, and
p values are shown in Table 1. d Common and unique broad peaks identified in regions encoding mRNAs in SNI and sham. ChIP-seq data were
generated from two IP samples each, for SNI and sham. Each sample contained L4, L5 and L6 ipsilateral DRG obtained from ten mice each, 4 weeks
after surgery. 3UTR 3′ untranslated region, 5UTR 5′ untranslated region, ncRNA noncoding RNA, Pseudo pseudo genes, rRNA ribosomal RNA, TTS
transcription termination sites

Table 1 Enriched binding for both coding and noncoding regions in SNI and sham control DRG and the p values
for Fig. 1c
Annotation Sham

SNI

Log2 enrich‑ p value
ment

Log2 enrich‑ p value
ment

3UTR

0.775

0

0.997

0

ncRNA

0.699

1.48699E−08

0.815

2.2653E−12

TTS

0.559

0

0.733

0

Pseudo

0.209

0.52247426

0.92

0.000232852

Exon

2.046

0

1.883

0

Intron

0.185

0

0.308

0

−0.278

0

0

1.136

0

−0.352

0.655

0

5UTR

1.958

0

1.196

0

rRNA

2.494

0.050658031

2.446

0.056264625

Intergenic
Promoter

Enriched MeCP2 binding to miRNAs

We then investigated changes in MeCP2 binding
to miRNAs after nerve injury. While miRNA-transcribed regions represent a much smaller fraction of
the genome compared to protein-coding genes, our
analysis highlighted a small number of miRNA loci
with distinct MeCP2 binding. A subsequent analysis

of MeCP2-bound sequence tags indicated that miRNA
regions were enriched for MeCP2 binding, and this
enrichment was observed in the SNI model (Fig. 3a).
However, within several miRNA regions identified as
MeCP2-enriched, binding was detected in only one
condition, sham or SNI, indicating different regulatory profiles in SNI versus sham. Our analysis showed
that 242 peaks were within 2 kb of miRNA regions in
sham and 271 peaks were within 2 kb of miRNA regions
in SNI. Based strictly on tag locations, there were 158
tags overlapping 76 miRNA regions in sham, and 297
tags overlapping 140 regions in SNI. Thus, a larger proportion of tags overlapped a larger number of miRNA
regions in SNI compared to sham. However, only a
minority of occupied miRNAs in SNI met the fourfold
cutoff for differential binding relative to sham. The miRNAs most enriched for MeCP2 binding, including 14
miRNAs with increased MeCP2 binding and 21 miRNAs with decreased binding in the SNI model relative
to sham, are shown in Fig. 3b. Our analysis showed that
miR-126 and miR-6340 had the largest fold enrichment
for SNI and sham, respectively (Additional file 3: Fig.
S1a and S1b). Since miR-126a and miR-126b had the
largest fold enrichment in the SNI model, we confirmed
MeCP2 binding to miR-126 locus by ChIP-PCR (Additional file 4: Fig. S2).
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Table 2 Gene ontology analysis of MeCP2 bound promoters
GO term

p value

q value FDR B&H

Hit count in query list

GO accession

RNA polymerase II transcription factor activity, sequencespecific DNA binding

2.09E−09

6.41E−06

214

GO:0000981

Transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding

7.30E−08

1.12E−04

125

GO:0001228

Transcription factor activity, RNA polymerase II core promoter 1.13E−07
proximal region sequence-specific binding

1.16E−04

126

GO:0000982

Enzyme binding

3.44E−06

2.12E−03

500

GO:0019899

Regulatory region DNA binding

3.82E−06

2.12E−03

247

GO:0000975

Transcription regulatory region DNA binding

4.16E−06

2.12E−03

246

GO:0044212

Regulatory region nucleic acid binding

5.08E−06

2.23E−03

247

GO:0001067

Receptor binding

1.94E−05

5.74E−03

427

GO:0005102

Sequence-specific double-stranded DNA binding

2.10E−05

5.74E−03

211

GO:1990837

Double-stranded DNA binding

2.15E−05

5.74E−03

233

GO:0003690

Tissue development

7.05E−18

7.67E−14

595

GO:0009888

Skeletal system development

5.71E−17

3.11E−13

203

GO:0001501

Organ morphogenesis

9.09E−16

3.30E−12

345

GO:0009887

Regulation of multicellular organismal

3.00E−15

7.71E−12

541

GO:2000026

Regulation of cell differentiation

3.54E−15

7.71E−12

509

GO:0045595

Regulation of nervous system development

6.60E−15

1.20E−11

292

GO:0051960

Neurogenesis

8.78E−15

1.37E−11

557

GO:0022008

Regulation of cell development

4.71E−14

6.42E−11

316

GO:0060284

Generation of neurons

1.11E−13

1.34E−10

528

GO:0048699

Positive regulation of cell differentiation

3.12E−13

3.28E−10

309

GO:0045597

Neuron projection

2.19E−08

2.77E−05

333

GO:0043005

Neuron part

1.99E−07

1.26E−04

409

GO:0097458

Somatodendritic compartment

1.93E−06

8.17E−04

246

GO:0036477

Cell body

8.24E−06

1.86E−03

197

GO:0044297

Integral component of plasma membrane

8.41E−06

1.86E−03

427

GO:0005887

Neuronal cell body

8.81E−06

1.86E−03

178

GO:0043025

Anchoring junction

1.21E−05

2.19E−03

152

GO:0070161

Intrinsic component of plasma membrane

1.66E−05

2.63E−03

440

GO:0031226

Potassium channel complex

2.10E−05

2.96E−03

38

GO:0034705

Adherens junction

3.00E−05

3.80E−03

145

GO:0005912

Molecular function

Biological process

Cellular component

The top ten enriched gene ontology (GO) terms with p < 0.01 are listed for molecular function, biological process, and cellular component, respectively. GO analysis
of our ChIP-seq results indicates that MeCP2 binding occurs at the promoter of genes with neuronal function, ion channel activity and cellular membrane functions.
These results closely correspond with previous reports of genes repressed by MeCP2 in brain [16]

Upon confirmation, we pursued further characterization and significance of enriched MeCP2 binding to the
miR-126.
miR‑126 locus has enriched MeCP2 binding in SNI

The peak profile for miR-126 locus from ChIP-seq shows
enrichment for MeCP2 binding over input control and
sham samples (Fig. 4a). We observed an enrichment of
MeCP2 binding to miR-126 locus after nerve injury, with
virtually no binding in the sham sample. This indicates

that nerve injury induced an increase in MeCP2 binding to miR-126 locus, and hence, we further explored the
functional consequences of this binding in the context of
nerve injury-induced pain.
Methylation of miR‑126 locus

Cytosine methylation of CpG dinucleotides is recognized as a crucial epigenetic modification. Since MeCP2
is a methyl DNA binding protein, we wanted to investigate whether increased MeCP2 binding to miR-126 locus
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Fig. 2 Redistribution of MeCP2 binding in the DRG after nerve injury. a Genome-wide distribution of enriched peaks representing putative MeCP2
binding sites that are at least fourfold higher in the SNI model compared to sham control. b Genomic redistribution of MeCP2 binding determined
by enriched peaks in the SNI, and sham model indicates increased MeCP2 binding to transcriptionally relevant regions and noncoding RNAs. 3UTR
3′ untranslated region, 5UTR 5′ untranslated region, ncRNA noncoding RNA, Pseudo pseudo genes, rRNA ribosomal RNA, TTS transcription termination sites; NS not significant *p value <1 × 10−3

Table 3 Top ten MeCP2-enriched promoters and genes identified by ChIP-seq in the DRG from SNI model compared
to sham control
Nearest refseq

Gene name

Gene description

Tag count

p value

Sham

SNI

Promoters with enriched MeCP2 binding
NM_021478

Tulp1

Tubby like protein 1

0

30

2.85E−06

NM_027398

Kcnip1

Kv channel-interacting protein 1

0

19

0.000195

NM_170757

Ccdc186

Coiled-coil domain containing 186

0

16

0.000629

NM_001034898

Ms4a15

Membrane-spanning 4-domains, subfamily A, member 15

0

25

1.92E−05

NR_033168

Snora28

Small nucleolar RNA, H/ACA box 28

0

26

1.31E−05

NM_001113379

Lrrc32

Leucine rich repeat containing 32

0

25

1.92E−05

NM_011305

Rxra

Retinoid X receptor alpha

0

15

0.000932

NM_018820

Sertad1

SERTA domain containing 1

0

17

0.000425

NM_001011525

Olfr1415

Olfactory receptor 1415

0

16

0.000629

NM_133759

Zbtb3

Zinc finger and BTB domain containing 3

0

25

1.92E−05

Gene bodies with enriched MeCP2 binding
NM_001001807

Olfr279

Olfactory receptor 279

0

21

8.97E−05

NM_011540

Tcap

Titin-cap

0

16

0.000629

NM_011971

Psmb3

Proteasome (prosome, macropain) subunit, beta type 3

0

19

0.000195

NM_198414

Paqr9

Progestin and adipoQ receptor family member IX

0

20

0.000132

NM_133668

Slc25a3

Solute carrier family 25 (mitochondrial carrier, phosphate carrier), member 3

0

15

0.000932

NM_001160356

Uqcc3

Ubiquinol-cytochrome c reductase complex assembly factor 3

0

15

0.000932

NM_001190356

Gm4832

Predicted gene 4832

0

15

0.000932

NM_133759

Zbtb3

Zinc finger and BTB domain containing 3

0

25

1.92E−05

NM_009296

Supt4a

Suppressor of Ty 4A

0

20

0.000132

NM_009756

Bmp10

Bone morphogenetic protein 10

0

18

0.000288

observed in the DRG from the SNI model was due to
changes in methylation pattern. Our analysis of the 72-bp
sequence of premiR-126 locus revealed the presence of
6 CpG sites. To evaluate whether SNI surgery caused

alterations in the methylation status of premiR-126 locus,
we performed bisulfite sequencing of DRG genomic DNA
obtained from SNI and sham control mice 4 weeks after
surgery. Our analysis of the methylation status showed
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decreased Dnmt1 expression compared to untransfected
cells (Fig. 5c). Based on the decrease in both transcript
and protein levels, we conclude that miR-126 regulates
expression of both Dnmt1 and Vegfa through degradation of mRNA.
Repression of miR‑126 and upregulation of its target genes
in the SNI model

Fig. 3 Enriched MeCP2 binding to miRNAs in the SNI model. a
miRNA tag enrichment is greater in the SNI model compared to sham
control, suggesting altered MeCP2-mediated regulation of miRNAs
after nerve injury p value 1.2 × 10−3. b miRNAs listed have at least
fourfold tag enrichment in the SNI or sham model. miR-126 was the
miRNA with the highest tag enrichment in the SNI model

that all 6 CpG sites were methylated in both SNI and
sham samples (Fig. 4b). This identical methylation patterns in SNI and sham control mice indicates that nerve
injury did not alter the methylation status of premiR-126
locus. Since there was an increase in MeCP2 bound to
premiR-126 after nerve injury, we postulate that MeCP2
redistribution throughout the genome and the specific
enrichment at miR-126 could be induced by alterations
in the availability of the genome for MeCP2 binding, after
nerve injury. The location of miR-126 is within the Egfl7
gene, and the expression levels of miR-126 correlate with
expression of Egfl7 [30]. We therefore investigated methylation at the Egfl7 promoter which had a CpG island.
Bisulfite sequencing at the putative promoter of miR-126
showed that there were no changes in CpG methylation
(data not shown).
miR‑126 regulates expression of Dnmt1 and Vegfa in Neuro
2a cells

The Neuro 2a mouse neuroblastoma cell line was used to
investigate regulation of target gene expression by miR126. Previous studies have demonstrated direct binding
of miR-126 to the 3′ untranslated region (UTR) of vascular endothelial growth factor (Vegfa) [31] and DNA
methyltransferase 1 (Dnmt1) [32]. Neuro 2a cells were
transfected with miR-126 precursor plasmid, or scrambled miRNA control, expressing GFP. We observed a
decrease in mRNA (Fig. 5a) and protein levels (Fig. 5b)
of Dnmt1 and Vegfa 72 h after miR-126 transfection. We also show that miR-126-transfected cells have

We next sought to determine the consequence of
increased MeCP2 binding to miR-126 locus in the DRG
after nerve injury. There was a significant decrease of
miR-126 in the DRG after SNI (Fig. 6a). This indicates
that increased binding of MeCP2 represses transcription
of miR-126. We hypothesized that reduced levels of miR126 would result in increased expression of miR-126 target genes in the DRG. An increase in Dnmt1 and Vegfa
transcripts was observed in the SNI model (Fig. 6b, c).
Western blot analysis confirmed an increase in Dnmt1
protein (Fig. 6d). However, we did not observe significant
changes in Vegfa protein in the DRG (Fig. 6e). Previous
studies have shown that peripheral nerve injury leads
to upregulation of Vegfa in accumulating neutrophils
and macrophages in the peripheral nerve [33]. Vegfa is
a secreted protein; therefore, protein expression in the
DRG may not reflect miR-126-mediated regulation of
Vegfa. Based on our in vitro data and reduced transcript
levels of both target genes in the DRG after SNI, we conclude that downregulation of miR-126 levels resulting
from MeCP2 binding can contribute to the upregulation
of Dnmt1 and Vegfa after nerve injury.
Expression of miR‑126 and target genes Dnmt1 and Vegfa
in DRG from Mecp2‑null mice

To further confirm the regulatory role of MeCP2 on
miR-126 expression, we obtained DRG from Mecp2null mice. We assessed miR-126 levels in Mecp2-null
mice and found that there were no significant differences compared to wild-type littermates (Fig. 7a). This
finding along with our observation from the SNI model
indicates that MeCP2 does not regulate expression of
miR-126 under naïve conditions. However, there was
increased MeCP2 binding to miR-126 upon nerve injury,
resulting in miR-126 repression. Since miR-126 is a
negative regulator of Dnmt1 and Vegfa, we wanted to
investigate whether MeCP2 can also affect expression of
these genes. Thus, we assessed mRNA levels of Dnmt1
and Vegfa in the DRG of Mecp2-null mice to determine
the regulatory role of MeCP2. These mice do not have
detectable levels of MeCP2. Our qPCR results showed
a downregulation of Dnmt1 (Fig. 7b) and Vegfa (Fig. 7c)
in the DRG in the absence of MeCP2, suggesting that
MeCP2 may directly or indirectly regulate the activation
of these genes.
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Fig. 4 miR-126 locus has enriched MeCP2 binding in SNI model. a MeCP2 peak profile from ChIP-seq at miR-126a/miR-126b shows enrichment of
MeCP2 binding to miR-126 locus in the SNI model, and virtually no binding in the sham control. b CpG methylation of miR-126 locus was identical
in SNI and sham control mice. Bisulfite sequencing of the 72-bp sequence of premiR-126 locus harboring 6 CpG sites using DRG genomic DNA
obtained from SNI and sham control mice showed methylation of all CpG sites in both SNI and sham samples (n = 3). Identical methylation pattern
in SNI and sham control indicates that SNI does not alter the methylation pattern of premiR-126 locus

Overexpression of miR‑126 in vivo did not alter pain
threshold but decreased target gene expression

We observed regulation of Dnmt1 and Vegfa by miR-126
in Neuro 2a cells, and an inverse correlation in expression
of miR-126 and its target genes in the DRG after nerve
injury. To investigate whether upregulation of miR-126 can
alter pain threshold in the SNI model mice, we intrathecally administered exogenous miR-126. An intrathecal
catheter was implanted 4 weeks after SNI surgery, to allow
for repeated administration of 2 nmol miR-126 or control miRNA. We did not observe a change in mechanical
(Fig. 8a) or thermal (data not shown) hypersensitivity in
these mice, after overexpressing miR-126. With the lack
of efficacy in pain behavior studies, we wanted to confirm
miR-126 delivery to the DRG and investigate changes in

Vegfa and Dnmt1 expression. Over fivefold higher levels of miR-126 was detected in the DRG from mice that
received miR-126 compared to those injected with control
miRNA (Fig. 8b), thus confirming uptake of miR-126 by
the DRG. Additionally, delivery of miR-126 robustly downregulated Dnmt1 and Vegfa mRNA in the DRG (Fig. 8c).
These results indicate that though the delivery of miR126 decreased Dnmt1 and Vegfa expression in the DRG,
this was not sufficient to reverse nerve injury-induced
mechanical and thermal hypersensitivity.

Discussion
This study provides evidence indicating that peripheral
nerve injury induces redistribution of MeCP2 binding in the DRG. MeCP2 is implicated in pain because of
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Fig. 5 miR-126 regulates expression of Dnmt1 and Vegfa in vitro. a Relative expression of endogenous Dnmt1 and Vegfa mRNA in Neuro 2a cells
transfected with miR-126 Gapdh was used as a normalizer. b Representative Western blot of Dnmt1 and Vegfa using lysate of Neuro 2a cells transfected with miR-126 precursor plasmid for 72 h. Overexpression of miR-126 decreased mRNA and protein levels of Dnmt1 and Vegfa; beta tubulin
was used as the control. c Immunohistochemistry indicating transfection with miR-126 plasmid co-expressing GFP in Neuro 2a cells decreased
Dnmt1 levels compared to untransfected cells 72 h post-transfection. Significance determined using unpaired Student’s t test, p value *<0.05,
***<0.001 (n = 3 for all samples)

the abnormal thresholds observed in RTT patients [7].
Studies assessing the pain threshold of mice with aberrant MeCP2 expression, mimicking those observed in
patients, have shown reduced sensitivity [8–11]. Collectively, these studies indicate that precise regulation of
MeCP2 levels is crucial for normal pain thresholds. We
had previously observed an upregulation of MeCP2 in
the DRG 4 weeks after SNI. DRG neurons have been the
focus of much research to identify molecular targets of
pain neurotransmission because they represent primary
sites for pain processing. Our data show that increased
MeCP2 expression after peripheral nerve injury can
induce differential binding of MeCP2 to the genome. This
may play a crucial role in bringing about either direct or
indirect global gene-regulatory changes associated with
chronic pain.
MeCP2 has high affinity for methylated cytosines that
are followed by a guanine nucleotide (mCG) [1]. MeCP2
binds broadly throughout the genome in a DNA methylation-dependent manner. It is now known that MeCP2 can
bind two alternatively methylated forms of DNA including methylated cytosine followed by a nucleotide other
than guanine (mCH, where H = A, C or T) and hydroxymethylcytosine (hmC) [34, 35]. Both mCH and hmC are
enriched in human and mouse brain, but there are no

reports to date on the status of these alternately methylated forms of DNA in the DRG. In general, mCH appears
to be a repressive mark that inhibits gene expression [35,
36]. The occurrence of hmC within gene bodies, however,
has been associated with active gene expression in neurons [34, 36]. Our ChIP-seq data suggest a genome-wide
shift in the binding pattern of MeCP2 after nerve injury,
including three thousand distinct mRNA encoding sites.
There also seems to be redistribution from binding at
intergenic regions to an overall increase in binding to
transcriptionally relevant regions and noncoding RNAs.
MeCP2 quantification in post-mitotic neurons showed
that it is nearly as abundant as the histone octamer. It
was suggested that genome-wide binding of MeCP2 in a
DNA methylation-dependent manner may dampen transcriptional noise and MeCP2 may contribute to the basic
structure of neuronal chromatin [5]. MeCP2 was shown
to modulate transcription in a gene-length-dependent
manner, and preferential upregulation was observed for
long genes enriched for methylated CpA dinuleotides
in brain from Mecp2-null mice [16]. Our tag enrichment analyses were more sensitive to binding changes in
longer genes, simply because statistical power increases
with tag count, and longer regions (gene bodies) have
more changes of MeCP2 binding. Hence, our approach
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Fig. 6 Expression of miR-126 and its target genes Dnmt1 and Vegfa in the DRG after nerve injury. a Relative expression of miR-126 determined by
qPCR shows a reduction in miR-126 in SNI model compared to DRG from sham control. U6 was used for normalization (n = 8 sham, n = 7 SNI). b
Relative expression of Dnmt1 mRNA and c Vegfa transcripts showed an increase in the DRG after nerve injury compared to control (n = 3). Gapdh
was used as a normalizer. d Representative Western blot and quantification showed an increase of Dnmt1 protein in the DRG after nerve injury. e
Western blot and quantification showed Vegfa protein was not significantly different in DRG after nerve injury (n = 3 from pooled samples, three
DRG were pooled for each sample). Significance determined using unpaired Student’s t test, p value *<0.05

Fig. 7 Expression of miR-126 and its target genes Dnmt1 and Vegfa in the DRG from Mecp2-null mouse. a Relative expression of miR-126 in the
DRG showed comparable expression in Mecp2-null and wild-type littermates. U6 was used for normalization. b Dnmt1 and c Vegfa expression
was decreased in the DRG from Mecp2-null mouse, indicating MeCP2 has a role in regulating expression of Dnmt1 and Vegfa. Gapdh was used as
a normalizer. Significance determined using unpaired Student’s t test, p value *<0.05, **<0.01 n = 3 for Mecp2-null (−/y) and wild-type littermate
mice (+/y)

detected stronger binding differences in large genes.
Thus, binding of MeCP2 at mCG, mCH and hmC along
with the accompanying alteration in chromatin architecture can collectively play a role in regulating gene expression in mature neurons.
Neurons in the DRG are surrounded by an envelope of satellite glial cells, and it is well established that
immune and glial cell responses alter neuronal function in the peripheral and central nervous system [37].

Our ChIP-seq study was performed using whole DRG,
and thus, the findings reported here is from a mixed
cell population. Comparison of cell-specific global DNA
methylation along with gene expression data will enable
comparative study to confirm whether methylationinduced changes in MeCP2 binding resulted in gene
expression changes. Plasticity of DNA methylation
was recently investigated in rat DRG 24 h after spinal
nerve ligation, another peripheral nerve injury model of
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Fig. 8 Administration of exogenous miR-126 decreased Dnmt1 and Vegfa expression in vivo but did not alter pain sensitivity. a Mechanical sensitivity measured by von Frey filaments showed that intrathecal delivery of miR-126 did not alter the paw withdrawal threshold in SNI model mice.
Arrows indicate daily intrathecal injections with 2 nmol miR-126 or control miRNA via catheter (n = 5 for miR-126 and miR-control injected mice,
n = 3 for PBS injected mice). b Confirmation of miR-126 delivery to DRG. A qPCR performed using DRG collected from mice injected with miR-126
or control miRNA showed an increase in miR-126 in mice that received miR-126 compared to miR-control injected mice indicating successful delivery. c Relative expression of Dnmt1 and Vegfa mRNA in the DRG of miR-126 and control injected mice. Increased miR-126 decreased the expression
of endogenous Dnmt1 and Vegfa compared to miR-control injected mice. Significance determined using unpaired Student’s t test, p value, **<0.01,
***<0.001 (n = 5 for miR-126 and miR-control injected mice, n = 3 for PBS injected mice). d Schematic representation of nerve injury-induced
alterations of MeCP2 and downstream gene expression changes. SNI induced enriched binding of MeCP2 to miR-126 locus resulting in repression
of miR-126. Lower miR-126 leads to increased expression of its two target genes Vegfa and Dnmt1. Vegfa could contribute to the progression of
pain pathology by modulating angiogenesis and neuro-inflammation. Dnmt1 propagate established methylation patterns during cellular division
by recognizing and copying parent strand methylation at symmetrical CG dinucleotides to the newly synthesized daughter strand and its increase
after SNI can alter or maintain methylation, and may contribute to gene expression changes ensuing SNI

neuropathic pain. Though there was widespread remodeling of DNA methylation, comparison of genome-wide
methylation and RNA-seq analysis of promoter regions
and gene bodies showed that variation of methylation
was not tightly linked with differences in gene expression
[38]. The impact of DNA methylation on transcription is
context dependent because methylation has been shown
to either inhibit or promote gene expression, depending on the location of the mark [39]. MeCP2 is an abundantly expressed protein that seems to bind throughout
the genome, and therefore, it is plausible that in addition
to regulating specific target genes, MeCP2 may broadly
affect genome-wide transcription.
MeCP2 alters gene expression through several mechanisms, but MeCP2 function itself is regulated by miRNAs
and several posttranslational modifications including
activity-dependent phosphorylation [40]. MeCP2 also
suppress miRNA biogenesis by directly binding to
DiGeorge syndrome critical region 8 (DGCR8), a critical
component of the nuclear miRNA-processing machinery
[41]. MeCP2-bound sequence tags indicated that miRNA

regions were enriched for MeCP2 binding in the SNI
model compared to sham control. It has been proposed
that the functions of miRNAs are more pronounced
under stress or disease states [42], and alterations in
MeCP2 binding could be one of the mechanisms contributing changes in miRNA expression.
To investigate the impact of nerve injury-induced redistribution, we studied miR-126, the miRNA with highest enrichment for MeCP2 binding post-nerve injury.
miR-126 is encoded within the intron of Egfl7 and highly
expressed in brain [43]. A recent study demonstrated a
role for miR-126 in reducing inflammation and improving the functional deficit after spinal cord injury. miR-126
decrease promoted angiogenesis and inflammation in the
spinal cord after a weight induced contusion and administration of miR-126 reduced locomotor deficit and tissue damage [44]. We have previously observed a decrease
in miR-126 in L4 and L5 DRG in rats 4 weeks after spinal nerve ligation [45]. Hsa-miR-126 was downregulating in whole blood from patients with complex regional
pain syndrome compared to healthy donors [46] and in
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exosomes from CRPS patients compared to that of control [47]. Nerve injury induced upregulation of MeCP2
and a decrease in miR-126 in mice after SNI. There was
no MeCP2 binding at the miR-126 locus in sham control
mice. Furthermore, Mecp2-null mice and their wild-type
littermates have similar levels of miR-126. This indicates
that nerve injury induces the enriched binding of MeCP2
to miR-126 locus, resulting in miR-126 repression. We
also observed increased expression of Vegfa and Dnmt1
in the SNI model. Dnmt1 and Vegfa are two validated target genes of miR-126 [31, 32]. Both genes are implicated
to have a role in peripheral pain mechanisms. Dnmt1 is
necessary for maintenance methylation, gene regulation, and chromatin stability [48]. Dnmt1 mutations in
humans contribute to hereditary sensory neuropathy
[49] and autonomic neuropathy [50]. Our current study
and others have shown upregulation of Dnmt1 in the
DRG after peripheral nerve injury [51]. Vegfa regulates
angiogenesis in both development and various pathologies [52]. In the chronic constriction injury model of neuropathic pain, Vegfa and its receptor was upregulated in
the DRG, and addition of anti-Vegf antibody increased
thermal and mechanical withdrawal latency [53]. We
observed increased Vegfa mRNA in the DRG after SNI.
miR-126 regulation of these targets is further supported
by our molecular studies. Mecp2-null mice had reduced
levels of Dnmt1 and Vegfa. Reduced transcript levels in
Mecp2-null mice can be interpreted as MeCP2 having a
role in activation of these genes. Since we did not observe
a significant binding of MeCP2 to Dnmt1 and Vegfa, one
of the indirect mechanisms contributing to their upregulation after SNI could be the repression of miR-126 by
MeCP2.
DNA methylation is a stable epigenetic modification.
Since SNI and sham DRG had an identical methylation
pattern at miR-126 locus, increased binding of MeCP2
to miR-126 can be considered to be independent of the
methylation status, but dependent on nerve injury. Likely,
nerve injury changes the chromatin architecture, allowing increased access for MeCP2 to bind miR-126 locus.
Further studies are needed to explore the role of MeCP2
in altering chromatin availability.
Administration of miR-126 did not alter the pain
threshold in mice after SNI, and this could be due to the
severity of nerve injury used to generate chronic neuropathic pain in the SNI model. miRNAs are fine tuners of
gene expression, and the low pain threshold generated
by SNI could have been too severe for a single miRNA
to reverse. Acting as a rheostat, the influence of miRNAs is often described as modest. As was reported for
the studies in a spinal cord injury model [44], the role of
miR-126 in reversing inflammation and functional deficits could not be captured in the evoked pain behavioral
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assessments we employed. Future studies in less severe
nerve injury or inflammatory pain models that may capture the involvement of Vegfa should be explored. Several
miRNAs showed changes in MeCP2 binding after SNI.
Administering these miRNAs, either individually or as a
cocktail of several miRNAs, to regulate a larger number
of downstream target genes, could potentially be beneficial in conferring analgesic effects.

Conclusions
Decreased pain perception in children with RTT suggests that MeCP2 function is important in modulating
pain. Our ChIP-seq analysis to determine the functional
implication of increased MeCP2 in the DRG after nerve
injury showed redistribution, and enrichment within
transcribed regions in the SNI model compared to sham
control. For miRNA regions, enriched binding was
detected only in sham or SNI, indicating different regulatory profiles in SNI versus sham DRG. Distinct binding patterns of MeCP2 in SNI could therefore mediate
gene expression changes following nerve injury. Enriched
MeCP2 binding to miR-126 locus after nerve injury
repressed miR-126 expression, and this was not mediated by alterations in methylation pattern at the miR-126
locus. Downregulation of miR-126 resulted in the upregulation of its two target genes Dnmt1 and Vegfa. These
target genes were significantly downregulated in Mecp2null mice compared to wild-type littermates, indicating a
regulatory role for MeCP2 in activating Dnmt1 and Vegfa
expression. Intrathecal delivery of miR-126 decreased
Dnmt1 and Vegfa expression in the DRG, but was not
sufficient to reverse nerve injury-induced mechanical
and thermal hypersensitivity. Collectively, these studies
show that MeCP2 broadly binds chromatin and therefore can influence numerous downstream targets. The
findings from this study provide the molecular basis for
a better understanding of how epigenetic changes induce
alterations in gene expression that occur in the DRG after
nerve injury.
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